share_log

United Therapeutics | 10-Q: Q3 2024 Earnings Report

United Therapeutics | 10-Q: Q3 2024 Earnings Report

美國聯合醫療 | 10-Q:2024財年三季報
美股SEC公告 ·  2024/10/30 18:37

牛牛AI助理已提取核心訊息

United Therapeutics reported strong financial results for Q3 2024, with total revenues increasing 23% to $748.9 million compared to $609.4 million in Q3 2023. Net income rose 16% to $309.1 million from $267.6 million year-over-year. The growth was primarily driven by Tyvaso product sales, which grew 33% to $433.8 million, led by Tyvaso DPI's 34% increase to $274.6 million.Operating expenses increased to $405.8 million from $282.4 million, including a $65.1 million litigation accrual related to ongoing litigation with Sandoz. The company maintained a strong balance sheet with $4.6 billion in cash and investments as of September 30, 2024. During the quarter, United Therapeutics completed its $1 billion share repurchase program, repurchasing approximately 3.5 million shares.The company continues to advance its pipeline, including phase 3 trials of nebulized Tyvaso for IPF and PPF indications, and the ADVANCE OUTCOMES study of ralinepag for PAH. Management highlighted progress in xenotransplantation programs, with plans to submit an IND for the UKidney product following recent FDA feedback. The company also expanded manufacturing capacity with a new clinical-scale designated pathogen-free facility in Virginia.
United Therapeutics reported strong financial results for Q3 2024, with total revenues increasing 23% to $748.9 million compared to $609.4 million in Q3 2023. Net income rose 16% to $309.1 million from $267.6 million year-over-year. The growth was primarily driven by Tyvaso product sales, which grew 33% to $433.8 million, led by Tyvaso DPI's 34% increase to $274.6 million.Operating expenses increased to $405.8 million from $282.4 million, including a $65.1 million litigation accrual related to ongoing litigation with Sandoz. The company maintained a strong balance sheet with $4.6 billion in cash and investments as of September 30, 2024. During the quarter, United Therapeutics completed its $1 billion share repurchase program, repurchasing approximately 3.5 million shares.The company continues to advance its pipeline, including phase 3 trials of nebulized Tyvaso for IPF and PPF indications, and the ADVANCE OUTCOMES study of ralinepag for PAH. Management highlighted progress in xenotransplantation programs, with plans to submit an IND for the UKidney product following recent FDA feedback. The company also expanded manufacturing capacity with a new clinical-scale designated pathogen-free facility in Virginia.
美國聯合醫療報告了2024年第三季度的強勁財務業績,總收入同比增長23%,達到74890萬,上一年第三季度爲60940萬。凈利潤同比上升16%,從26760萬增至30910萬。增長主要得益於Tyvaso產品的銷售,銷售額增長33%,達到43380萬,其中Tyvaso DPI的銷售額增長34%,達到27460萬。營業費用從28240萬增加至40580萬,其中包括與Sandoz持續訴訟相關的6510萬訴訟準備金。截至2024年9月30日,公司保持了強勁的資產負債表,現金和投資總額達到46億。在該季度內,美國聯合醫療完成了10億的股份回購計劃,回購了大約350萬股。公司繼續推進其管道,包括針對IPF...展開全部
美國聯合醫療報告了2024年第三季度的強勁財務業績,總收入同比增長23%,達到74890萬,上一年第三季度爲60940萬。凈利潤同比上升16%,從26760萬增至30910萬。增長主要得益於Tyvaso產品的銷售,銷售額增長33%,達到43380萬,其中Tyvaso DPI的銷售額增長34%,達到27460萬。營業費用從28240萬增加至40580萬,其中包括與Sandoz持續訴訟相關的6510萬訴訟準備金。截至2024年9月30日,公司保持了強勁的資產負債表,現金和投資總額達到46億。在該季度內,美國聯合醫療完成了10億的股份回購計劃,回購了大約350萬股。公司繼續推進其管道,包括針對IPF和PPF適應症的霧化Tyvaso的三期試驗,以及針對PAH的ralinepag的ADVANCE OUTCOMES研究。管理層強調了異種移植項目的進展,計劃在最近獲得FDA反饋後提交UKidney產品的IND申請。公司還在弗吉尼亞州擴展了製造能力,新增了一座臨牀規模的指定無病原體設施。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。